Results 11 to 20 of about 10,125,713 (289)

Fructose and Non-Alcoholic Steatohepatitis [PDF]

Frontiers in Pharmacology, 2021
Background: The excessive consumption of free sugars is mainly responsible for the high prevalence of obesity and metabolic syndrome in industrialized countries.
Elke Roeb, Ralf Weiskirchen
doaj   +4 more sources

Non-alcoholic Steatohepatitis: An Overview

Journal of the Formosan Medical Association, 2009
Non-alcoholic fatty liver disease (NAFLD) includes a broad spectrum of fat-induced liver injury, ranging from mild steatosis to cirrhosis and liver failure.
Allison Shifflet, George Y. Wu
doaj   +3 more sources

Therapies for non-alcoholic steatohepatitis

Liver Research, 2017
Current phase 3 trials for the treatment of non-alcoholic steatohepatitis (NASH) are discussed in this review. Modalities that are based on weight loss include therapeutic lifestyle changes, pharmacological weight loss drugs (e.g., orlistat), and ...
Winston Dunn
doaj   +2 more sources

Can Pharmacologic Therapy Induce Histologic Improvement in Non-alcoholic Steatohepatitis?

The Korean Journal of Gastroenterology, 2016
Articles: Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-cirrhotic, Non-alcoholic Steatohepatitis (FLINT): a Multicentre, Randomised, Placebo-controlled Trial (Lancet 2015;385:956-965) Liraglutide Safety and Efficacy in Patients with Non ...
Nae-Yun Heo
doaj   +2 more sources

Endocannabinoids and non-alcoholic steatohepatitis

The Saudi Journal of Gastroenterology, 2006
Non alcoholic steatohepatitis (NASH) has gained a lot of attention recently due to the increased prevalence of diabetes, obesity, and hyperlipedemia. The endogenous compounds, endocannabinoids (ECBs), bind to the same receptors as tetrahydrocannabinol ...
Helmy Ahmed
doaj   +3 more sources

Inhibition of connexin hemichannels alleviates non-alcoholic steatohepatitis in mice [PDF]

Scientific Reports, 2017
While gap junctions mediate intercellular communication and support liver homeostasis, connexin hemichannels are preferentially opened by pathological stimuli, including inflammation and oxidative stress.
Joost Willebrords, Bruno Cogliati, Isabel Veloso Alves Pereira, Tereza Cristina da Silva, Sara Crespo Yanguas, Michaël Maes, Veronica Mollica Govoni, Andressa Lima, Daniele Aparecida Felisbino, Elke Decrock, Marina Sayuri Nogueira, Inar Alves de Castro, Isabelle Leclercq, Luc Leybaert, Robim Marcelino Rodrigues, Mathieu Vinken   +15 more
doaj   +2 more sources

Comparison of clinical, biochemical and histological features of alcoholic steatohepatitis and non-alcoholic steatohepatitis in Asian Indian patients

Indian Journal of Pathology and Microbiology, 2010
Background: Alcoholic steatohepatitis (ASH) and non-alcoholic steatohepatitis (NASH) are significant forms of liver disease and may progress to end-stage liver disease, cirrhosis and potentially malignant complications.
Singh Deepak, Rastogi Archana, Sakhuja Puja, Gondal Ranjana, Sarin Shiv   +4 more
doaj   +1 more source

Alcoholic and non-alcoholic steatohepatitis [PDF]

Experimental and Molecular Pathology, 2014
This paper is based upon the “Charles Lieber Satellite Symposia” organized by Manuela G. Neuman at the Research Society on Alcoholism (RSA) Annual Meetings, 2013 and 2014. The present review includes pre-clinical, translational and clinical research that characterize alcoholic liver disease (ALD) and non-alcoholic steatohepatitis (NASH). In addition, a
Manuela G, Neuman, Samuel W, French, Barbara A, French, Helmut K, Seitz, Lawrence B, Cohen, Sebastian, Mueller, Natalia A, Osna, Kusum K, Kharbanda, Devanshi, Seth, Abraham, Bautista, Kyle J, Thompson, Iain H, McKillop, Irina A, Kirpich, Craig J, McClain, Ramon, Bataller, Radu M, Nanau, Mihai, Voiculescu, Mihai, Opris, Hong, Shen, Brittany, Tillman, Jun, Li, Hui, Liu, Paul G, Thomes, Murali, Ganesan, Steve, Malnick   +24 more
openaire   +2 more sources

Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis

Hepatology, EarlyView., 2022
Abstract Background and Aims Peroxisome proliferator‐activated receptor α (PPARα) regulates fatty acid transport and catabolism in liver. However, the role of intestinal PPARα in lipid homeostasis is largely unknown. Here, intestinal PPARα was examined for its modulation of obesity and NASH. Approach and Results Intestinal PPARα was activated and fatty
Tingting Yan, Yuhong Luo, Nana Yan, Keisuke Hamada, Nan Zhao, Yangliu Xia, Ping Wang, Changdong Zhao, Dan Qi, Shoumei Yang, Lulu Sun, Jie Cai, Qiong Wang, Changtao Jiang, Oksana Gavrilova, Kristopher W. Krausz, Daxesh P. Patel, Xiaoting Yu, Xuan Wu, Haiping Hao, Weiwei Liu, Aijuan Qu, Frank J. Gonzalez   +22 more
wiley   +1 more source

Treatment of non-alcoholic steatohepatitis [PDF]

Best Practice & Research Clinical Gastroenterology, 2002
Treatment of patients with non-alcoholic steatohepatitis (NASH) has typically been focused on the management of associated conditions such as obesity, diabetes mellitus and hyperlipidaemia. NASH associated with obesity may resolve with weight reduction, although the benefits of weight loss have been inconsistent.
Paul, Angulo, Keith D, Lindor
openaire   +2 more sources